Clinical trial
Evaluation of Glycemic Control and User Acceptability of the BD Ultra-Fine Nano 4 mm x 32G Pen Needle for Injection of Long-acting or Basal Insulin Doses Above 40 Units
NCT01334606 is registered in ClinicalTrials.gov with Becton, Dickinson and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Evaluation of Glycemic Control and User Acceptability of the BD Ultra-Fine Nano 4 mm x 32G Pen Needle for Injection of Long-acting or Basal Insulin Doses Above 40 Units
- Lead sponsor
- Becton, Dickinson and Company
- Phase
- Not applicable
- Overall status
- Terminated
- Start date
- March 31, 2011
- Completion date
- June 30, 2011
- Enrollment
- 21 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.